US M&A and equity raisings
3,392 deals since January 2025, with sources and adviser credits where available · as at 20 Nov 2026 · Venture rounds
Deals dated after 30 September 2026 are still being collected.
445 deals · US$333bndisclosed · Healthcare · Clear
Columns
| Date | Target | Vendor | Acquirer | Type | Status | Value US$m | Sector | Advisers |
|---|---|---|---|---|---|---|---|---|
| Jun 2026 | Remix Therapeutics | – | Passage Bio | Merger | Pending | – | Biotech+2 | Wedbush SecuritiesRBC Capital MarketsCanaccord GenuityLatham & Watkins (sell-side)Fenwick & West (buy-side) |
| Jun 2026 | Serapha Bio | – | Boundless Bio | Merger | Pending | – | Biotech+1 | Wedbush Securities (sell-side)Gibson Dunn (sell-side)Goodwin (sell-side)Lucid Capital Markets (buy-side)Latham & Watkins (buy-side) |
| Jun 2026 | Harloff Manufacturing | The Winsford Company | Capsa Healthcare | Asset sale | Announced | – | Medtech+1 | Mesirow (sell-side)Stout (sell-side) |
| Jun 2026 | Sangamo Therapeutics capsid delivery, zinc finger, modular integrase platforms and prion disease program | Sangamo Therapeutics | Eli Lilly and Company | Asset sale | Completed | – | Biotech+1 | Raymond JamesPaul, Weiss (buy-side) |
| Jun 2026 | Apogee Therapeutics | – | AbbVie | Acquisition | Pending | 10,900.0 | Biotech+2 | Goldman Sachs (sell-side)Jefferies (sell-side)Kirkland & Ellis (sell-side)Paul, Weiss (buy-side)Morgan Stanley (buy-side) |
| Jun 2026 | Validic | – | ChartSpan | Acquisition | Completed | – | Healthcare Software+1 | Oppenheimer & Co. (sell-side) |
| Jun 2026 | Xstim | Precision Medical Products | EBI | Asset sale | Completed | – | Medtech | William Blair (sell-side)Ashurst Perkins Coie (sell-side)Ropes & Gray (buy-side) |
| Jun 2026 | Simulations Plus | – | Affiliates of Altaris | Acquisition | Announced | 375.0 | Life Sciences+2 | Morgan Stanley (sell-side)Procopio, Cory, Hargreaves & Savitch (sell-side)Bass, Berry & Sims (buy-side)Truist Securities (buy-side)J.P. Morgan (buy-side)Kirkland & Ellis (buy-side)Latham & Watkins (buy-side) |
| Jun 2026 | WillowWood Holdings | Blue Sea Capital | CVC Catalyst III | Acquisition | Announced | – | Medtech | Weil, Gotshal & Manges (buy-side) |
| Jun 2026 | 4E Therapeutics | – | Eli Lilly and Company | Acquisition | Completed | – | Biotech+1 | Wilson Sonsini Goodrich & Rosati (sell-side) |
| Jun 2026 | SteriGear | – | HR HealthCare | Acquisition | Announced | – | Medtech | Dorsey & Whitney (sell-side)Miles & Stockbridge (buy-side) |
| Jun 2026 | Azora Therapeutics | – | Adial Pharmaceuticals | Asset sale | Completed | – | Biotech+2 | Lucid Capital Markets (sell-side)Honigman (sell-side)Oppenheimer & Co. (buy-side)Blank Rome (buy-side) |
| Jun 2026 | Riverpoint Medical | Arlington Capital Partners | Novanta | Acquisition | Announced | 1,200.0 | Medtech | Goodwin (sell-side)Baird (buy-side) |
| Jun 2026 | Nuvalent | – | GSK | Acquisition | Pending | 10,600.0 | Biotech+2 | Sullivan & CromwellCenterview Partners (sell-side)Ropes & Gray (sell-side)Jefferies (sell-side)Sidley Austin (sell-side)Leerink Partners (buy-side)Citi (buy-side)Davis Polk (buy-side)Slaughter and May (buy-side)Innisfree M&A (buy-side) |
| Jun 2026 | Ignite Proteomics | Aditxt | Proposed Ignite Proteomics Inc. holding company | Merger | Pending | 150.0 | Life Sciences+2 | Ladenburg Thalmann |
| Jun 2026 | Vega Therapeutics | Star Therapeutics | Incyte | Acquisition | Completed | 1,250.0 | Biotech+2 | Lazard (buy-side)Evercore (sell-side)Morgan Stanley (sell-side)Fenwick & West (sell-side)Goodwin (buy-side) |
| Jun 2026 | Standard BioTools | – | – | Merger | Pending | 460.0 | Biotech+2 | Wedbush Securities (sell-side)Fenwick & West (sell-side)Centerview Partners (buy-side)Freshfields (buy-side)Richards, Layton & Finger (buy-side)UBS (buy-side) |
| Jun 2026 | Vitalware mid-revenue cycle business | Health Catalyst | Med-Metrix | Asset sale | Completed | 147.0 | Healthcare Software+1 | Raymond James (sell-side)Latham & Watkins (sell-side) |
| Jun 2026 | Vesica Health | – | Photocure ASA | Acquisition | Completed | 30.5 | Diagnostics | DNB Carnegie (buy-side)Morgan Lewis (buy-side)Selmer (buy-side) |
| Jun 2026 | Genesis Molecular AI | – | Incyte | Stake | Announced | 40.0 | AI+1 | Goodwin (buy-side) |
| Jun 2026 | CMSPricer | – | Micro-Dyn Medical Systems | Acquisition | Announced | – | Healthcare Software+1 | Holland & Knight (buy-side) |
| Jun 2026 | The Riviera at Alexandria | – | Chiron Real Estate | Asset sale | Announced | 249.0 | Real Estate+1 | Vinson & Elkins (buy-side) |
| Jun 2026 | Healthcare real estate platform joint venture | – | Rethink Healthcare Real Estate | Joint venture | Announced | – | Real Estate+1 | Goodwin (buy-side) |
| Jun 2026 | Avenzo Therapeutics | – | Rallybio | Acquisition | Pending | – | Biotech+2 | Leerink Partners (sell-side)Cooley (sell-side)Evercore (buy-side)Citizens JMP (buy-side)Ropes & Gray (buy-side) |
| Jun 2026 | Sevasemten and Edgewise muscular dystrophy business | Edgewise Therapeutics | Servier | Asset sale | Completed | 1,550.0 | Biotech+2 | LazardCenterview Partners (sell-side)Wilson Sonsini Goodrich & Rosati (sell-side) |
| Jun 2026 | Family First Holding | Trivest Partners | Aveanna Healthcare Holdings | Acquisition | Completed | – | Healthcare Services | Baird (sell-side) |
| Jun 2026 | Obagi Medical dermatological skincare and aesthetics business | Waldencast | Bridgepoint | Asset sale | Announced | – | Skin Care+2 | LazardLatham & Watkins (buy-side) |
| Jun 2026 | US generic and specialty pharmaceutical product portfolio of Nordic Pharma | Nordic Pharma | J. Molner | Asset sale | Completed | – | Pharma | Raymond James |
| Jun 2026 | Kalderos | – | Model N | Acquisition | Announced | – | Healthcare Software+2 | Kirkland & Ellis (buy-side) |
| Jun 2026 | HST Pathways | – | Novo Holdings | Stake | Announced | – | Healthcare Software+1 | Kirkland & Ellis (sell-side) |
| Jun 2026 | Ramsoft | Level Equity | RF Investment Partners | Acquisition | Completed | – | Healthcare Software+1 | Raymond James |
| Jun 2026 | Tres Health | – | Sheridan Capital Partners | Stake | Completed | – | Healthcare | TripleTree |
| Jun 2026 | Healix | – | Singlepoint Healthcare | Acquisition | Completed | – | Healthcare Services | Raymond James |
| Jun 2026 | kneat.com | – | Thoma Bravo, L.P. | Acquisition | Pending | 453.6 | Vertical SaaS+1 | Kirkland & Ellis (buy-side) |
| Jun 2026 | Ensemble | – | Thoreau | Stake | Announced | – | Healthcare Services+1 | Kirkland & Ellis (buy-side) |
| Jun 2026 | Helio Health Group | – | WestView Capital Partners | Stake | Completed | – | AI+1 | Latham & Watkins (buy-side) |
| May 2026 | SCAP Hologram assets | SCAP Hologram | DePuy Synthes | Asset sale | Pending | – | Medtech | Goodwin (sell-side) |
| May 2026 | Altruix | WindRose Health Investors | Frazier Healthcare Partners | Acquisition | Completed | – | Behavioral Health+1 | Houlihan Lokey (sell-side)Cantor Fitzgerald (sell-side)Latham & Watkins (sell-side)Goodwin (buy-side) |
| May 2026 | VIP Petcare veterinary services business | PetIQ | Tractor Supply Company | Asset sale | Completed | – | Pet+2 | William Blair (sell-side)Davis Polk (sell-side)Centerview Partners (buy-side)Sidley Austin (buy-side) |
| May 2026 | AmbioPharm | – | CordenPharma | Acquisition | Announced | – | Pharma Services+2 | Kirkland & EllisBNP Paribas (sell-side)Latham & Watkins (buy-side) |
| May 2026 | Curevo Vaccine | – | Eli Lilly | Acquisition | Pending | 1,500.0 | Biotech+1 | Cooley (sell-side)Centerview Partners (sell-side) |
| May 2026 | Vaccine Company | – | Lilly | Acquisition | Announced | 1,550.0 | Biotech+1 | Lazard (sell-side)Cooley (sell-side) |
| May 2026 | Brain Institute | – | – | Merger | Announced | – | Healthcare Services | |
| May 2026 | Ennov Group | – | Bregal Sagemount | Stake | Announced | – | Healthcare Software+2 | Proskauer RoseGoodwin (buy-side) |
| May 2026 | Engage Bio | – | Eli Lilly | Acquisition | Announced | 202.0 | Biotech+1 | Cooley (sell-side) |
| May 2026 | Mentari Therapeutics | – | InMed Pharmaceuticals | Acquisition | Announced | – | Biotech+1 | Wedbush Securities (sell-side)Gibson Dunn (sell-side)Lucid Capital Markets (buy-side)Norton Rose Fulbright (buy-side) |
| May 2026 | Orphai Therapeutics | – | Quince Therapeutics | Acquisition | Completed | – | Biotech+2 | Cooley (sell-side)LifeSci Capital (buy-side)Dorsey & Whitney (buy-side)Oppenheimer & Co. (buy-side)Gibson Dunn (buy-side) |
| May 2026 | Omnicare business | Omnicare | GenieRx Holdings | Asset sale | Pending | – | Healthcare Services | Jenner & Block (sell-side)Haynes Boone (sell-side)Houlihan Lokey (sell-side)Alvarez & Marsal (sell-side) |
| May 2026 | Sutter Instrument Corp. | – | Lafayette Instrument | Acquisition | Completed | – | Manufacturing+2 | EC M&A (sell-side)Donahue Fitzgerald (sell-side)Akerman (buy-side)RSM (buy-side) |
| May 2026 | MacroGenics GMP manufacturing site and CDMO operations | MacroGenics | Bora Pharmaceuticals Co. | Asset sale | Completed | 122.5 | Pharmaceutical Manufacturing+1 | Moelis & Company (sell-side)Sidley Austin (sell-side)Covington & Burling (sell-side)Jones Day (buy-side) |
Deals come from SEC filings (merger proxies, tender offers, 8-K announcements and IPO prospectuses), the deal pages and transaction lists of law firms and banks, companies' press releases and the press. How the data is built